Marc Goodman Leerink Partners LLC, Research Division. Okay. We're going to get going on our next session. Thanks for joining us. I'm Marc Goodman, one of the biopharma analyst at ...

In the open-label FIBROMET trial, metformin treatment was associated with reductions in bone marrow fibrosis and downregulation of key oncogenic signaling pathways in patients wit ...

Extent of disease: Patients with 10% or less vitiligo and particularly facial or limited lesions tend to benefit most from ...

A new study highlights the value of JAK inhibitors (JAKi) for managing alopecia areata (AA) in Black and African American patient populations. The analysis appears in the International Journal of ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Eli Lilly LLY and Incyte INCY announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending the approval of ...

Clinicians most valued rapid achievement of ~75% regrowth, ranking convenience factors (oral route, once-daily dosing, monitoring burden) lowest among treatment goals. Oral JAK inhibitor use was ...

A punishing pathway and a peaceful pathway. That’s the story of the draw for this year’s Champions League knockout phase proper. By a twist of fate, Real Madrid has landed on the silver side of the ...

The Food and Drug Administration (FDA) announced a new proposal Monday for flexible drug approval pathway treatments addressing ultrarare diseases. The FDA unveiled draft guidance on a proposed ...

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...

After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, ...